IP Verse

Small Liposomes For Delivery Of Immunogen-Encoding Rna - EP4066819

The patent EP4066819 was granted to Glaxosmithkline on Mar 1, 2023. The application was originally filed on Aug 31, 2011 under application number EP22175210A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4066819

GLAXOSMITHKLINE
Application Number
EP22175210A
Filing Date
Aug 31, 2011
Status
Granted And Under Opposition
Jan 27, 2023
Grant Date
Mar 1, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JG OPPOSITIONSDec 1, 2023MEWBURN ELLISADMISSIBLE
BIONTECHNov 30, 2023HOPFNERADMISSIBLE
SANOFINov 30, 2023ELKINGTON AND FIFEADMISSIBLE
WEICKMANN & WEICKMANNNov 30, 2023-ADMISSIBLE

Patent Citations (25) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2011057020
OPPOSITIONEP4066819
OPPOSITIONWO02095023
OPPOSITIONWO2005007689
OPPOSITIONWO2005120152
OPPOSITIONWO2005121348
OPPOSITIONWO2007047749
OPPOSITIONWO2011005799
OPPOSITIONWO2011068810
OPPOSITIONWO2012006369
OPPOSITIONWO2012006376
OPPOSITIONWO2012006377
OPPOSITIONWO2012006378
OPPOSITIONWO2012030901
OPPOSITIONWO2014160243
OPPOSITIONWO2017075531
OPPOSITIONWO2018075980
OPPOSITIONWO2022137133
SEARCHEP0786522
SEARCHEP1637144
SEARCHJP2007112768
SEARCHUS5750390
SEARCHUS5972704
SEARCHWO2012006376
SEARCHWO9952503

Non-Patent Literature (NPL) Citations (57) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BOXUS et al., J Virol, (20070000), vol. 81, pages 6879 - 89-
DESCRIPTION- EL OUAHABI et al., FEBSLetts, (19960000), vol. 380, pages 108 - 12-
DESCRIPTION- "Functional Polymer Colloids and Microparticles", Microspheres, microcapsules & liposomes, Citus Books, (20020000), vol. 4-
DESCRIPTION- GIULIANI et al., Proc Natl Acad Sci USA, (20060000), vol. 103, no. 29, pages 10834 - 9-
DESCRIPTION- Handbook of Experimental Immunology, Blackwell Scientific Publications, (19860000), vol. I-IV-
DESCRIPTION- HEYES et al., J Controlled Release, (20050000), vol. 107, pages 276 - 87-
DESCRIPTION- JEFFS et al., Pharmaceutical Research, (20050000), vol. 22, no. 3, pages 362 - 372-
DESCRIPTION- JOHANNING et al., Nucleic Acids Res, (19950000), vol. 23, pages 1495 - 1501-
DESCRIPTION- "Liposomes: Methods and Protocols", Pharmaceutical Nanocarriers: Methods and Protocols, Humana Press, (20090000), vol. 1-
DESCRIPTION- "Liposome Technology", Informa Healthcare, (20060000), vol. I, II & III-
DESCRIPTION- MAURER et al., Biophysical Journal, (20010000), vol. 80, pages 2310 - 2326-
DESCRIPTION- PERRI et al., J Virol, (20030000), vol. 77, pages 10394 - 10403-
DESCRIPTION- TAYLOR et al., Vaccine, (20050000), vol. 23, pages 1242 - 50-
DESCRIPTION- YONEYAMAFUJITA, Cytokine & Growth Factor Reviews, (20070000), vol. 18, pages 545 - 51-
OPPOSITION- Anonymous, "Medical Virology Fourth Edition ", Anonymous, White David O, Fenner Frank J, Medical Virology, Academic Press, (19940101), pages 3 - 29, 434-435, 450-459, 538-541, ISBN 0-12-746642-8, XP093046091-
OPPOSITION- Anonymous, "Spikevax ( COVID-19 mRNA Vaccine (nucleoside modified) ) An overview of Spikevax, including its adapted vaccine, and why it is authorised in the EU", EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH, NL, NL, (20220101), pages 1 - 5, (20230928), XP093087018-
OPPOSITION- Bernstein, D.I. ; Reap, E.A. ; Katen, K. ; Watson, A. ; Smith, K. ; Norberg, P. ; Olmsted, R.A. ; Hoeper, A. ; Morris, J. ; Negri, S. ; Maughan, M.F. ; Chulay, J.D., "Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20091211), vol. 28, no. 2, ISSN 0264-410X, pages 484 - 493, XP026791388-
OPPOSITION- Dolgin Elie, "Trial settles debate over best design for mRNA in covid vaccines", Nature, (20230119), vol. 613, pages 419 - 420, XP093134290-
OPPOSITION- Heineman Thomas C, "Chapter 71 Human cytomegalovirus vaccines Authors", Heineman Thomas C, Ann Arvin , Gabriella Campadelli-Fiume , Edward Mocarski , Patrick S. Moore , Bernard Roizman , Richard Whitley , Koichi Yamanishi, Human Herpesviruses Biology, Therapy, and Immunoprophylaxis, (20070101), pages 1 - 25, XP093147575-
OPPOSITION- Heyes, J. ; Palmer, L. ; Bremner, K. ; MacLachlan, I., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", Journal of Controlled Release, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20051003), vol. 107, no. 2, ISSN 0168-3659, pages 276 - 287, XP027664137-
OPPOSITION- Immordino Maria Laura, Dosio Franco, Cattel Luigi, "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential", International journal of nanomedicine, Auckland , NZ, (20060101), vol. 1, no. 3, ISSN 1176-9114, pages 297 - 315, XP093146633-
OPPOSITION- Lowe Derek, "Curevac comes around", (20230126), pages 1 - 2, Science Blog: In the Pipeline, URL: https://www.science.org/content/blog-post/curevac-comes-around, (20240227), XP093135558-
OPPOSITION- MacLachlan I., "Liposomal formulations for nucleic acid delivery", MacLachlan I., CROOKE STANLEY T, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2ND ED., US , CRC PRESS , (20070101), pages 237 - 270, ISBN 978-0-8493-8796-8, XP002584305-
OPPOSITION- Morrison Trudy G., "Paramyxoviuses , infection and immunity", Encyclopedia of Immunology, (19980101), pages 1909 - 1916, XP093046089-
OPPOSITION- Steve Pascolo, "Chapter 7.2. Plasmid DNA and Messenger RNA for Therapy", Steve Pascolo, Shayne Cox, Handbook of Pharmaceutical Biotechnology, John Wiley & Sons , (20070601), pages 971 - 1011, doi:10.1002/9780470117118.ch07b, ISBN 978-0-471-21386-4, XP055626043
OPPOSITION- F Martinon , S Krishnan, G Lenzen, R Magné, E Gomard, J G Guillet, J P Lévy, P Meulien, "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA", European Journal of Immunology, Hoboken, USA, (19930701), vol. 23, doi:10.1002/eji.1830230749, ISSN 0014-2980, pages 1719 - 1722, XP002937540
OPPOSITION- Jeffs et al., "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, (2005), vol. 22, doi:10.1007/s11095-004-1873-z, page 3, XP019370801
OPPOSITION- Jeffs et al null, "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research , (2005), vol. 22, doi:10.1007/s11095-004-1873-z, XP019370801
OPPOSITION- Lloyd B. Jeffs ; Lorne R. Palmer ; Ellen G. Ambegia ; Cory Giesbrecht ; Shannon Ewanick ; Ian MacLachlan, "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NL, NL , (20050301), vol. 22, no. 3, doi:10.1007/s11095-004-1873-z, ISSN 1573-904X, pages 362 - 372, XP019370801
OPPOSITION- Lloyd B. Jeffs ; Lorne R. Palmer ; Ellen G. Ambegia ; Cory Giesbrecht ; Shannon Ewanick ; Ian MacLachlan, "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, NL , (20050301), vol. 22, no. 3, doi:10.1007/s11095-004-1873-z, ISSN 1573-904X, pages 362 - 372, XP019370801
OPPOSITION- Zhou X, Berglund P, Rhodes G, Parker S.E, Jondal M, Liljeström P, "Self-replicating Semliki Forest virus RNA as recombinant vaccine", Vaccine, AMSTERDAM, NL , (19941201), vol. 12, no. 16, doi:10.1016/0264-410X(94)90074-4, ISSN 0264-410X, pages 1510 - 1514, XP093134288
OPPOSITION- Minnaert et al., "Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across", Advanced Drug Discovery Reviews, (2021), vol. 176, doi:10.1016/j.addr.2021.113900, XP086773295
OPPOSITION- Schoenmaker Linde, Witzigmann Dominik, Kulkarni Jayesh A., Verbeke Rein, Kersten Gideon, Jiskoot Wim, Crommelin Daan J.A., "mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability", International Journal of Pharmaceutics, NL , (20210501), vol. 601, doi:10.1016/j.ijpharm.2021.120586, ISSN 0378-5173, pages 1 - 13, XP055828800
OPPOSITION- Heyes et al., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J Controlled Release, (2005), vol. 107, doi:10.1016/j.jconrel.2005.06.014, XP008157522
OPPOSITION- Heyes et al. null, "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J. Controlled Release, (2005), vol. 107, doi:10.1016/j.jconrel.2005.06.014, XP008157522
OPPOSITION- Hassett Kimberly J., Benenato Kerry E., Jacquinet Eric, Lee Aisha, Woods Angela, Yuzhakov Olga, Himansu Sunny, Deterling Jessica, Geilich Benjamin M., Ketova Tatiana, Mihai Cosmin, Lynn Andy, Mcfadyen Iain, Moore Melissa J., Senn Joseph J., Stanton Matthew G., Almarsson Örn, Ciaramella Giuseppe, Brito Luis A., "Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines", Molecular Therapy-Nucleic Acids, US , (20190415), vol. 15, doi:10.1016/j.omtn.2019.01.013, ISSN 2162-2531, pages 1 - 18, XP093147586
OPPOSITION- Geall Andrew J.; Mandl Christian W.; Ulmer Jeffrey B., "RNA: The new revolution in nucleic acid vaccines", Seminars in immunology, W.B. SAUNDERS COMPANY, PA., US, US , (19000101), vol. 25, no. 2, doi:10.1016/j.smim.2013.05.001, ISSN 1044-5323, pages 152 - 159, XP028694558
OPPOSITION- Kowalski et al., "Evaluation of neurovirulence and biodistribution of Venezuelan equine encephalitis replicon particles expressing herpes simplex virus type 2 glycoprotein D", Vaccine, (2007), vol. 25, doi:10.1016/j.vaccine.2006.11.063, XP005886449
OPPOSITION- Ulmer et al., "RNA-based vaccines", Vaccine, (2012), vol. 30, doi:10.1016/j.vaccine.2012.04.060, XP028520925
OPPOSITION- Norbert Maurer, Kim F. Wong, Holger Stark, Lenore Louie, Deirdre Mcintosh, Tabitha Wong, Peter Scherrer, Sean C. Semple, Pieter R. Cullis, "Spontaneous Entrapment of Polynucleotides upon Electrostatic Interaction with Ethanol-Destabilized Cationic Liposomes", Biophysical Journal, AMSTERDAM, NL, (20010501), vol. 80, no. 5, doi:10.1016/S0006-3495(01)76202-9, ISSN 0006-3495, pages 2310 - 2326, XP055550920
OPPOSITION- Karikó Katalin, Muramatsu Hiromi, Welsh Frank A, Ludwig János, Kato Hiroki, Akira Shizuo, Weissman Drew, "Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability", Molecular Therapy, US , (20081101), vol. 16, no. 11, doi:10.1038/mt.2008.200, ISSN 1525-0016, pages 1833 - 1840, XP093147613
OPPOSITION- Zimmermann Tracy S., Lee Amy C. H., Akinc Akin, Bramlage Birgit, Bumcrot David, Fedoruk Matthew N., Harborth Jens, Heyes James A., Jeffs Lloyd B., John Matthias, Judge Adam D., Lam Kieu, Mcclintock Kevin, Nechev Lubomir V., Palmer Lorne R., Racie Timothy, Röhl Ingo, Seiffert Stephan, Shanmugam Sumi, Sood Vandana, Soutschek Jürgen, Toudjarska Ivanka, Wheat Amanda J., Yaworski Ed, Zedalis William, Koteliansky Victor, Manoharan Muthiah, Vornlocher Hans-Peter, Maclachlan Ian, "RNAi-mediated gene silencing in non-human primates", Nature, Springer Nature Limited, (20060101), vol. 441, doi:10.1038/nature04688, ISSN 0028-0836, pages 111 - 114, XP093134286
OPPOSITION- David V Morrissey, Jennifer A Lockridge, Lucinda Shaw, Karin Blanchard, Kristi Jensen, Wendy Breen, Kimberly Hartsough, Lynn Machemer, Susan Radka, Vasant Jadhav, Narendra Vaish, Shawn Zinnen, Chandra Vargeese, Keith Bowman, Chris S Shaffer, Lloyd B Jeffs, Adam Judge, Ian MacLachlan & Barry Polisky, "Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs", Nature Biotechnology, New York, (20050801), vol. 23, no. 8, doi:10.1038/nbt1122, ISSN 1087-0156, pages 1002 - 1007, XP008157520
OPPOSITION- Petsch et al., "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", Nature Biotechnology, (2012), vol. 30, doi:10.1038/nbt.2436, page 12, XP055051005
OPPOSITION- Sahin et al., "mRNA-based therapeutics - developing a new class of drugs", Nature Reviews Drug Discover, (2014), vol. 13, doi:10.1038/nrd4278, XP055544673
OPPOSITION- Akinc Akin; Maier Martin A.; Manoharan Muthiah; Fitzgerald Kevin; Jayaraman Muthusamy; Barros Scott; Ansell Steven; Du Xinyao; Hope Michael J.; Madden Thomas D.; Mui Barbara L.; Semple Sean C.; Tam Ying K.; Ciufolini Marco; Witzigmann Dominik; Kulkarni Jayesh A.; van der Meel Roy; Cullis Pieter R., "The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs", Nature nanotechnology, London , (20191201), vol. 14, no. 12, doi:10.1038/s41565-019-0591-y, ISSN 1748-3387, pages 1084 - 1087, XP036953174
OPPOSITION- Norbert Pardi, Michael J. Hogan, Martin S. Naradikian et al, "Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses", Journal of Experimental Medicine, US , (20180604), vol. 215, no. 6, doi:10.1084/jem.20171450, ISSN 0022-1007, pages 1571 - 1588, XP055545604
OPPOSITION- Fleeton et al., "Self-Replicative RNA Vaccines Elicit Protection against Influenza A Virus, Respiratory Syncytial Virus, and a Tickborne Encephalitis Virus", J. Infectious Diseases, (2001), vol. 183, doi:10.1086/319857, XP002224503
OPPOSITION- W Z Zhou , D S Hoon, S K Huang, S Fujii, K Hashimoto, R Morishita, Y Kaneda, "RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization.", Human gene therapy, GB , (19991101), vol. 10, no. 16, doi:10.1089/10430349950016762, ISSN 1043-0342, pages 2719 - 2724, XP002660042
OPPOSITION- Ian MacLachlan, "CHAPTER 9. Liposomal Formulations for Nucleic Acid Delivery", Ian MacLachlan, Stanley T Crooke, Antisense Drug Technology, Second Edition, CRC Press, (20070101), pages 237 - 270, XP093133162
OPPOSITION- Pascolo S, "Vaccination with messenger RNA", METHODS IN MOLECULAR MEDICINE, Humana Press, (20060101), ISSN 1543-1894, pages 23 - 40, XP009117840
OPPOSITION- Pascolo Steve, "Messenger RNA-based vaccines", Expert opinion on biological therapy, (20040801), vol. 4, no. 8, doi:10.1517/14712598.4.8.1285, ISSN 1471-2598, pages 1285 - 1294, XP009095328
OPPOSITION- Deering Raquel P; Kommareddy Sushma; Ulmer Jeffrey B, "Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.", Expert opinion on drug delivery, Informa Healthcare, UK, UK , (20140601), vol. 11, no. 6, doi:10.1517/17425247.2014.901308, ISSN 1744-7593, pages 885 - 899, XP009183535
OPPOSITION- Morais Pedro, Adachi Hironori, Yu Yi-Tao, "The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines", Frontiers in Cell and Developmental Biology, (20211104), vol. 9, doi:10.3389/fcell.2021.789427, pages 1 - 9, XP055885272
OPPOSITION- Preda Madalina, Manolescu Loredana Sabina Cornelia, Chivu Razvan Daniel, "Advances in Alpha Herpes Viruses Vaccines for Human", Vaccines, CH , (20230101), vol. 11, no. 6, doi:10.3390/vaccines11061094, ISSN 2076-393X, pages 1 - 21, XP093147629
OPPOSITION- Karl-Josef Kallen, Regina Heidenreich, Margit Schnee, Benjamin Petsch, Thomas Schlake, Andreas Thess, Patrick Baumhof, Birgit Scheel, Sven D Koch, Mariola Fotin-Mleczek, "A novel, disruptive vaccination technology: Self-adjuvanted RNActive® vaccines", Human vaccines & immunotherapeutics, (20131001), vol. 9, no. 10, doi:10.4161/hv.25181, ISSN 21645515, pages 2263 - 2276, XP055126357
OPPOSITION- Schlake et al., "Developing mRNA-vaccine technologies", RNA Biology, (2012), vol. 9, doi:10.4161/rna.22269, page 11, XP055126360

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents